chondrocyte

(redirected from chondro)
Also found in: Dictionary, Encyclopedia.
Related to chondro: chondromalacia, chondrosarcoma

chondrocyte

 [kon´dro-sīt]
one of the cells embedded in the lacunae of the cartilage matrix. adj., adj chondrocyt´ic.

chon·dro·cyte

(kon'drō-sīt),
A cartilage cell that occupies a lacuna within the cartilage matrix.
Synonym(s): cartilage cell
[chondro- + G. kytos, a hollow (cell)]

chondrocyte

(kŏn′drə-sīt′)
n.
A cartilage cell located in a lacuna of the cartilage matrix.

chon·dro·cyte

(kon'drō-sīt)
A nondividing cartilage cell; occupies a lacuna within the cartilage matrix.
[chondro- + G. kytos, a hollow (cell)]
References in periodicals archive ?
Chondro also owns 114 East 1st Street, a 17,610 s/f building with 30 residential units.
The lesion histologically appeared like chondroma/well differentiated Chondro sarcoma.
van Beuningen et al., "Overexpression of active TGF-beta-1 in the murine knee joint: evidence for synovial-layer-dependent chondro osteophyte formation," Osteoarthritis and Cartilage, vol.
A syndrome characterized by ectodermal dysplasia, polydactyly, chondro dysplasia and congenital morbuscordis--report of three cases.
There is also evidence that Aceclofenac stimulates the synthesis of IL-1 receptor antagonist in human articular chondrocytes subjected to inflammatory stimuli (35) and that 4'-hydroxyaceclofenac has chondro protective properties attributable to suppression of IL-1 mediated promatrix metalloproteinase production and proteoglycan release (36,37).
There is also evidence that Aceclofenac stimulates the synthesis of IL-1 receptor antagonist in human articular chondrocytes subjected to inflammatory stimuli (36) and that 4'-hydroxyaceclofenac has chondro protective properties attributable to suppression of IL-1 mediated promatrix metalloproteinase production and proteoglycan release (37,38).
Chondrogenesis: The ASC culture was performed from cell "Micromass" starting with a high concentration of cells in a minimal volume (1 x [10.sup.5] cells/100 [micro]l) in the presence of TGF-[beta] 1 and 3 (10 ng/ml), Asc 2P (50 [micro]M), and insulin (6.25 [micro]g/ml) (Chondro BulletKit; Lonza Co.) for four weeks with medium changes every 3 days.